Melbourne: Access to a variety of PrEP (pre-exposure prophylaxis) methods allows women to choose what best suits them, depending on their context and where they are in their reproductive lifespan. Oral pre-exposure prophylaxis or PrEP are medications that are highly effective at reducing the risk of HIV transmission, but they don’t work for everyone. HIV has been around for more than 40 years, yet it remains a major public health problem. While HIV is commonly thought of as an infection that predominantly affects men who have sex with men, 53 per cent of people living with HIV in 2022 were women and girls.
Also Read: Why Stigma Remains The Biggest Challenge In The Fight Against HIV
And of the 1.3 million new HIV infections that year, 46 per cent were among adolescent girls and women, the majority living in sub-Saharan Africa.
Driving down new HIV infections is a key part of achieving a 90 per cent reduction in HIV infections by 2030, as called for in the Sustainable Development Goals.
But it will require access to a variety of prevention methods to ensure all those at risk of contracting HIV can choose methods that best suit their circumstances.
Eliminating HIV transmission currently relies on using anti-retroviral drugs in two different ways.
The first is ‘treatment as prevention’, whereby the viral load in someone living with HIV is suppressed to undetectable levels.
This strategy underpins UNAIDS 90-90-90 campaign to test 90 per cent of individuals, ensure that 90 per cent of these individuals are on treatment, and that 90 per cent of these individuals are fully suppressed to decrease transmission of HIV.
A study published earlier this year in The Lancet confirmed that if someone’s viral load is less than 1,000 copies of the HIV virus per millilitre of bodily fluids, the risk of HIV transmission through sex is virtually zero. This finding supports the Undetectable = Untransmittable (U=U) global campaign.
The second strategy is HIV pre-exposure prophylaxis, or PrEP, in which anti-retroviral drugs are used to protect individuals at high risk of acquiring HIV through sex from their partners.
First generation HIV PrEP was approved in 2012. An oral pill called Truvada combines two anti-retroviral drugs, tenofovir disoproxil and emtricitabine, which target reverse transcriptase, a key HIV protein the virus needs to reproduce.
Oral PrEP works, as long as those using it remember to take it.
Also Read: Need Rigorous Multi-Media Campaign To Create Awareness On HIV/AIDS: MoS Health SP Singh Baghel
Men can miss some doses of PrEP and still be protected from HIV, but oral PrEP is less forgiving if a woman misses taking her daily pill.
Daily pills are needed to maintain protective drug levels in the vagina, which is the main route of HIV acquisition in women. In contrast, higher drug levels are reached in the rectum, which is the main route of HIV entry in men who have sex with men.
Context is important is understanding why women don’t just take their daily oral PrEP.
Oral PrEP use in adolescent girls and young women in sub-Saharan Africa is associated with stigma due to lack of pill storage options, which makes discrete use of the medication difficult, and side effects.
In addition, daily oral regimens are challenging for adolescent girls and young women to stick to. While adherence might be high at the start of taking oral PrEP, it decreases over time.
Having the ability to choose from and access a variety of PrEP methods allows women to choose what suits their different contexts and what is suitable at different points of their reproductive lifespans.
Women may prefer PrEP that is delivered in a different way — for example, via injection or implant, or vaginally — as well as medication that is longer-acting and requires less frequent dosing — for example, once every two months or less often, as opposed to daily.
Choice and diversity of options resulting in an increase in adherence and uptake is well established for contraceptives to prevent unplanned pregnancies. The same options could be provided for women to protect themselves against acquiring HIV.
Also Read: “Awareness About HIV/AIDS Have Reduced Stigma Around It”: Mona Balani, HIV/TB Activist
Second-generation PrEP options include the long-acting injectable cabotegravir. Cabotegravir belongs to the class of HIV drugs called integrase inhibitors. It is delivered into the body by intramuscular injections once every eight weeks for protection against HIV.
A phase three randomised clinical trial performed in seven countries in sub-Saharan Africa showed that the efficacy of injectable cabotegravir was greater when compared to daily oral Truvada for preventing HIV in uninfected cisgender women. Only four women became infected in the cabotegravir group, compared with 36 in the Truvada group.
While oral and injectable PrEP medications are effective, not all women want to take systemic forms of PrEP, because of fear of side effects. These women may prefer a topical form of PrEP, for example direct delivery of the antiretroviral drug into the vagina.
Vaginal delivery of drugs is an untapped frontier for drug discovery.
For topical PrEP, this has the advantage of delivering high anti-retroviral drug levels locally in the vagina, with minimal drug levels in a woman’s system, minimal side effects and a reduced chance of the virus becoming resistant to the drug.
Vaginal delivery can come in a variety of forms, including gels, tablets, films and intravaginal rings.
However, the only form of topical PrEP that has so far shown efficacy in preventing HIV infection in phase three clinical studies is the dapivirine ring.
The dapivirine ring is the only PrEP strategy specifically designed for women. It is an intravaginal ring made of flexible silicone loaded with 25mg of the antiretroviral drug, dapivirine, which is gradually released into the vagina over a four-week period.
Also Read: “Need To Reach Out To Vulnerable Communities To Achieve Zero New HIV/AIDS Cases”: J.V.R Prasad Rao
Phase three studies showed the dapivirine ring could reduce HIV acquisition by 30 per cent compared to a placebo ring, with efficacy being lower in women younger than 21 years of age due to low adherence.
However, follow-up studies with the dapivirine ring showed that it could provide about 50 per cent or more protection if used consistently.
The ring received WHO pre-qualification in 2020 and has regulatory approvals in a limited number of countries, including Kenya, Rwanda, South Africa, Uganda and Zimbabwe.
There are also devices in the development stage that go one step further, called multipurpose prevention technologies.
These include intravaginal rings designed to not only prevent HIV but also prevent unplanned pregnancy and even treat bacterial vaginosis.
Bacterial vaginosis commonly occurs when the bacteria living in a woman’s vagina are out of balance.
The condition results in vaginal inflammation and increases the risk of a woman acquiring HIV and other STIs, as well as increasing the risk of other adverse sexual and reproductive health outcomes.
In contrast, women who have an optimal vaginal microbiome, dominated by beneficial bacteria, are protected against HIV.
A product delivering molecules to the vagina that can target or prevent bacterial vaginosis as well as prevent HIV may also increase the efficacy of topical PrEP.
One device addressing multiple targets has the advantage of potentially addressing stigma associated with an agent specifically being used to prevent HIV, in addition to improving compliance and ultimately effectiveness.
Women having choice and access to diverse biomedical HIV prevention strategies and input into the design of these interventions will be important for achieving the goal of eliminating HIV transmission by 2030.
Also Read: Meet ‘Appa’ Who Runs A Shelter For HIV Positive Children In Chennai
(This story has not been edited by NDTV staff and is published from a syndicated feed.)
NDTV – Dettol have been working towards a clean and healthy India since 2014 via the Banega Swachh India initiative, which in its Season 10 is helmed by Campaign Ambassador Ayushmann Khurrana. The campaign aims to highlight the inter-dependency of humans and the environment, and of humans on one another with the focus on One Health, One Planet, One Future – Leaving No One Behind. It stresses on the need to take care of, and consider, everyone’s health in India – especially vulnerable communities – the LGBTQ population, indigenous people, India’s different tribes, ethnic and linguistic minorities, people with disabilities, migrants, geographically remote populations, gender and sexual minorities. In a world post COVID-19 pandemic, the need for WASH (Water, Sanitation and Hygiene) is reaffirmed as handwashing is one of the ways to prevent Coronavirus infection and other diseases. The campaign will continue to raise awareness on the same along with focussing on the importance of nutrition and healthcare for women and children, fight malnutrition, mental well-being, self-care, science and health, adolescent health & gender awareness. Along with the health of people, the campaign has realised the need to also take care of the health of the eco-system. Our environment is fragile due to human activity, which is not only over-exploiting available resources, but also generating immense pollution as a result of using and extracting those resources. The imbalance has also led to immense biodiversity loss that has caused one of the biggest threats to human survival – climate change. It has now been described as a “code red for humanity.” The campaign will continue to cover issues like air pollution, waste management, plastic ban, manual scavenging and sanitation workers and menstrual hygiene. Banega Swasth India will also be taking forward the dream of Swasth Bharat, the campaign feels that only a Swachh or clean India where toilets are used and open defecation free (ODF) status achieved as part of the Swachh Bharat Abhiyan launched by Prime Minister Narendra Modi in 2014, can eradicate diseases like diahorrea and the country can become a Swasth or healthy India.
